Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

RaNA Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on platform that allows selective gene activation and therapeutic factor expression by targeting long, noncoding RNA, closed a $20.7M Series A financing. Participants include Monsanto, SR One and Atlas Venture.

SpringLeaf Therapeutics (Boston, MA) a preclinical-stage biopharmaceutical company focused on novel delivery mechanisms, closed a $4M Series B financing, bringing the total round to $19M. Participants include Excel Venture Management, SR One, Flybridge Capital Partners and North Bridge Venture Partners. Thanx for your patience as we catch-up.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The 2Q11 OnBioVC Trend Analysis will [...]

SpringLeaf Therapeutics (Boston, MA) a preclinical stealth biopharmaceutical company, closed a $15M Series B financing. Participants include SR One, Flybridge Capital Partners and North Bridge Venture Partners.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Genocea Biosciences (Cambridge, MA) a preclinical-stage therapeutic vaccine developer focused on chlamydia trachomatis, streptococcus pneumonia and herpes simplex virus type 2 infections, closed a $35M Series B financing. Participants include Johnson & Johnson Dev Corp., Skyline Ventures, MP Healthcare Management, SR One, Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture [...]

Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $4M Series B financing, bringing the total round to $29M. Participants include SR One, Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins [...]

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

CalciMedica (La Jolla, CA) a preclinical-stage small molecule company focused on autoimmune and inflammatory via the inhibition of calcium release-activated calcium (CRAC) channels, closed a $5M Series C financing, bringing the total round up to $9M. Participants include Biogen Idec, Sanderling Ventures and SR One. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

  

to top of page...